ClinicalTrials.gg

Schizophrenia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,571 studies for Schizophrenia across more than 10 countries. 494 are recruiting or about to start. 3,024 of them are mainly about Schizophrenia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Schizophrenia, Treatment-Resistant too: 3,597 studies, 504 open.

ClinicalTrials.gov finds 4,272 studies for Schizophrenia. How that becomes 3,567 here

This page counts the studies the registry files under Schizophrenia, and those it files under no condition that list Schizophreniathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 4,272Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −26Filed under a narrower condition, counted on its own pageSchizophrenia, Treatment-Resistant 24
  3. −87List Schizophrenia as a condition, but the registry did not file them under itMost often written as “Schizophrenia Spectrum and Other Psychotic Disorders” (21), “Schizophrenia and Disorders With Psychotic Features” (11), and “Prodromal Schizophrenia” (11). The registry filed them under other conditions only, most often Schizophrenia Spectrum and Other Psychotic Disorders (33) and Psychotic Disorders (31).
  4. −592Match it another way99 name it in the title, 14 in a keyword, and 479 by a synonym or other text the search reads.
  5. 3,567The count on this page81 of them list Schizophrenia in their own words; the registry filed them under no condition.

Status

Completed
2,352
Status unknown
343
Recruiting
333
Terminated
244
Not yet recruiting
138
Withdrawn
78

Phase

Phase 3
474
Phase 2
461
Phase 4
452
Phase 1
376
Early Phase 1
28

Where

United States
1,465
China
250
France
240
Canada
193
Taiwan
181
Germany
179

Who develops what

Add Schizophrenia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 50 programs from 35 companies, 48 with this as their studies’ main aim; 14 with a live phase 3 study; 15 primary completions in the next 12 months. Compare Boryung Pharmaceutical, Bristol-Myers Squibb and Humanis Saglık Anonim Sirketi here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AripiprazoleRecent, repeated
Evidence
  • NCT07911787 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · comparator · “Aripiprazole” · registered Oct 2026
  • NCT07843056 · EMS · Phase 2 · comparator · “Aripiprazole (Fixed dose)” · registered Sep 2026
  • NCT07703956 · Vigonvita Life Sciences · Phase 2 · live · comparator · “Aripiprazole tablet” · registered Jul 2026
  • NCT07550387 · Hansoh Pharmaceutical Group Company Limited · Phase 2 · comparator · “Aripiprazole” · registered Apr 2026
  • NCT06589817 · Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Phase 3 · live · comparator · “Aripiprazole tablets” · registered Sep 2024
Otsuka Holdings Co., Ltd.85% of its industry studiesUS: off-patent, 25 generics marketedEU: off-patent, 4 generics authorized45 studies
OlanzapineRecent, repeated
Evidence
  • NCT06649214 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Olanzapine” · registered Oct 2024
  • NCT05303064 · Alkermes, Inc. · Phase 3 · live · comparator · “Olanzapine” · registered Mar 2022
  • NCT03557931 · Astellas Pharma Inc · Phase 2 · background · “olanzapine” · registered Jun 2018
  • NCT03187769 · Alkermes, Inc. · Phase 3 · comparator · “Olanzapine” · registered Jun 2017
  • NCT02694328 · Alkermes, Inc. · Phase 3 · comparator · “Olanzapine” · registered Feb 2016
Eli Lilly and Company47% of its industry studiesUS: off-patent, 30 generics marketedEU: off-patent, 7 generics authorized22 studies

11 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
evenamide hydrochloride☆ Track1 live phase-3 study: NCT07184619Newron Pharmaceuticals SPA
LB-102☆ Track2 live phase-3 studies: NCT07369154, NCT07363577LB Pharmaceuticals Inc.
Brexpiprazole for ER injection, 45 mg☆ Track1 live phase-3 study: NCT07742280Bostal Drug Delivery Co., Ltd
30 mg B2227☆ Track1 live phase-3 study: NCT07722728Bostal Drug Delivery Co., Ltd
cariprazineApproved: US 2015 · EU 2017☆ Track1 live phase-3 study: NCT07722728Bostal Drug Delivery Co., Ltd

The 5 in phase 3 with the nearest primary completion, of 50 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (15)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.NS-136 · NeuShen Therapeutics · Phase 2 main aimNCT07521683 A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia — primary endpoint: Positive And Negative Syndrome Scale(PANSS )score · 150 enrolled
  • 31 Dec 2026 est.Cariprazine Depot, cariprazine · Mapi Pharma Ltd. · Phase 2 main aimNCT07185815 Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine — primary endpoint: Safety, rate of adverse events (AEs) · 24 enrolled
  • 31 Mar 2027 est.evenamide hydrochloride · Newron Pharmaceuticals SPA · Phase 3 named, not the main aimNCT07184619 Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia — primary endpoint: Change from baseline to endpoint (Week 12) on the total score of the Positive and Negative Syndrome Scale (PANSS). · 400 enrolled

12 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Schizophrenia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antipsychotics 22 open · Antimuscarinics 8 open · GLP-1 receptor agonists 3 open · Stimulants 1 open · Opioid antagonists 1 open

Coming up

167studies finish main data collection within a year12 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger. 42 (13%) take children under 18. 2 (1%) are for women only and 1 (<1%) for men only; 83 (25%) take healthy volunteers.

Recruiting studies that take each age, of 333
AgeWomenMen
1011 (3%)11 (3%)
18301 (90%)300 (90%)
30316 (95%)315 (95%)
40296 (89%)295 (89%)
50273 (82%)273 (82%)
65186 (56%)185 (56%)
7580 (24%)80 (24%)
8570 (21%)70 (21%)

Across all 3,571 studies, recruiting or not: 80% stop at 75 or younger and 74% at 65; 10% take children; 1% are for women only and 3% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Schizophrenia studies take

Of 133 phase 1 interventional studies under Schizophrenia, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 112 mo5–19 · 133 studies9 mo5–16 · 108 studies—
Phase 1/254 mo22–70 · 18 studies——
Phase 225 mo15–42 · 101 studies20 mo12–32 · 57 studies43 mo25–73 · 44 studies
Phase 332 mo20–46 · 113 studies32 mo20–41 · 99 studies—
Phase 439 mo20–63 · 88 studies—48 mo27–64 · 71 studies
Interventional, no phase32 mo16–56 · 773 studies—33 mo17–56 · 760 studies
Observational47 mo27–102 · 136 studies—53 mo26–114 · 114 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered21

Show 16 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,571. Browse all 3,571 → or search them.